Corticotropin-releasing factor antagonists as novel psychotherapeutics

Drugs of the Future

Volumn 25, Issue 9, 2000, Pages 923-931

  Gutman, D A ^a   Owens, M J ^a   Nemeroff, C B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; COMPLEMENTARY DNA; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR[9-41]; MESSENGER RNA; NBI 30545; NGD 98 1; PD 171729; RECEPTOR SUBTYPE; SC 241; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DEPRESSION; HORMONE RELEASE; HUMAN; NEUROENDOCRINOLOGY; NONHUMAN; PSYCHOPHARMACOLOGY; RAT; REVIEW; STRESS;

EID: 0033732167     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.09.665577     Document Type: Review

References (58)

1. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin
2. Physiology and pharmacology of corticotropin-releasing factor
3. Corticotropin releasing factor, stress, and depression
4. Corticotropin-releasing factor receptors: From molecular biology to drug design
5. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor
6. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims
7. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression
8. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain
9. Expression of corticotropin-releasing factor and its receptors in the brain of lean and obese Zucker rats
10. 1 receptor mRNA expression
11. Amygdaloid CRF pathways. Role in autonomic, neuroendocrine, and behavioral responses to stress
12. The role of corticotropin-releasing factor in depression and anxiety disorders
13. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain
14. The neurobiology of depression
15. Synthetic competitive antagonists of corticotropin-releasing factor: Effect on ACTH secretion in the rat
16. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor 1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats
17. The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats
18. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems
19. CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat
20. Flumazenil prevents the development of chlordiazepoxide withdrawal in rats tested in the social interaction test of anxiety
21. Corticotropin-releasing factor antagonist attenuates the 'anxiogenic-like' effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats
22. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis
23. Localization of ligand-binding domains of human corticotropin-releasing factor receptor: A chimeric receptor approach
24. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors
25. Recent progress in corticotropin-releasing factor receptor agents
26. Corticotropin-releasing factor receptor antagonists
27. 1 receptor: Design of small molecule inhibitors, receptor subtypes and clinical indications
28. CP-154,526: A potent and selective non-peptide antagonist of corticotropin releasing factor receptors
29. A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity
30. 1 receptor antagonist
31. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: Behavioral, endocrine and neurochemical effects in the rat
32. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: A centrally active corticotropin-releasing factor 1 receptor antagonist
33. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation
34. Chronic effects of a nonpeptide corticotropin-releasing hormone type 1 receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation
35. Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress
36. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress
37. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates
38. 1 antagonists
39. 2 receptors: Membrane homogenate and autoradiographic studies
40. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines
41. Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines
42. Corticotropin-releasing hormone receptor antagonists: Framework design and synthesis guided by ligand conformational studies
43. The evaluation of CRF receptor antagonists in animal models
44. Effects of a non-peptide CRH antagonist on the HPA axis
45. Non-peptide corticotropin releasing factor antagonists mitigate behavioral sequelae of maternal separation
46. Novel small molecule CRF1 receptor antagonists: Identification and pharmacological characterization
47. Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor 1 receptor antagonists
48. Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: Application to the synthesis and optimization of corticotropin-releasing factor1 receptor antagonists
49. 1 receptor antagonist: NBI 27914
50. 1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: In vivo evidence using a novel, selective, non-peptide CRF receptor antagonist
51. CRF receptor regulation of stress-induced behavioral inhibition: An important role for R1 receptors in lateral septum and R1 receptors in amygdala
52. Effects of R121919 on CRF and stress-induced elevations in ACTH release and locomotor activity in the rat
53. Brain penetrance, receptor occupancy and anti-stress in vivo efficacy of a small molecule corticotropin-releasing factor 1 receptor selective antagonist
54. 1-selective antagonist, R121919, in the rat
55. 1 antagonist, R121919, attenuates the behavioral and neuroendocrine response to precipitated morphine or lorazepam withdrawal
56. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated
57. 1 receptor PET/SPECT ligands
58. 1 receptor